Platelet Rich Plasma for Knee Osteoarthritis
- Conditions
- Platelet-rich PlasmaOsteo Arthritis Knee
- Interventions
- Other: Platelet-rich plasma
- Registration Number
- NCT03197441
- Lead Sponsor
- Pei-Yuan Lee, MD
- Brief Summary
This study aimed to analyze the effect of platelet-rich plasma (PRP) on knee osteoarthritis. Eligible patients will undertake arthroscopic knee surgery plus intraoperative PRP and also receive second look surgery and intraoperative biopsy.
- Detailed Description
Osteoarthritis is a chronic disease defined by progressive degradation of the joint as well as loss of cartilage on joint surfaces. The degeneration that occurs in the joint leads to changes in the catabolic and anabolic activity of chondrocytes. Osteoarthritis may induce pain, stiffness and limitation in range of motion of the joint and also may impact the quality of life. Platelet-rich plasma (PRP) is a fraction of plasma that contains platelets and multiple growth factors concentrated at high level. Because activated platelets have the potential to release growth factors, PRP has been clinically used to accelerate wound healing and tissue regeneration in orthopedic and oral surgery. Although several studies have assessed the effects of PRP on knee osteoarthritis, a higher level of evidence has not been provided. This study aimed to analyze the effect of PRP on knee osteoarthritis. After performing arthroscopic knee surgery plus intraoperative PRP in eligible patients, a second look arthroscopic surgery with intraoperative biopsy will be arranged 6 months later. Pre- and post-operative imaging and clinical outcomes will also be compared.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
- Age between 30 and 70 years
- With diagnosis of osteoarthritis, grade II~grade IV, II-III medial compartment
- Lateral compartment and patellofemoral joint osteoarthritis
- With prior history of knee surgery
- Severe varus deformity
- With current or prior history of traum or infection at the knee
- With current or prior history of cancer
- With current or prior history of hematological disease
- Pregnancy
- Patients who will not cooperate with one-year followup
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description PRP group Platelet-rich plasma Arthroscopic knee surgery plus intraoperative platelet-rich plasma
- Primary Outcome Measures
Name Time Method Change in knee function from baseline to postoperative 3 months 3-month postoperative Knee function is evaluated using Oswestry Disability Index preoperatively and 3-month postoperatively.
- Secondary Outcome Measures
Name Time Method Change in knee function from baseline to postoperative 6 months 6-month postoperative Knee function is evaluated using Oswestry Disability Index preoperatively and 6-month postoperatively.
Change in knee function from baseline to postoperative 12 months 12-month postoperative Knee function is evaluated using Oswestry Disability Index preoperatively and 12-month postoperatively.
Change in knee pain from baseline to postoperative 3 months 3-month postoperative Pain is evaluated using visual analogue scale preoperatively and 3-month postoperatively.
Change in knee pain from baseline to postoperative 6 months 6-month postoperative Pain is evaluated using visual analogue scale preoperatively and 6-month postoperatively.
Change in knee pain from baseline to postoperative 12 months 12-month postoperative Pain is evaluated using visual analogue scale preoperatively and 12-month postoperatively.
Percentage of patients with regenerated cartilage 12-month postoperative Cartilage regeneration is assessed by pathological biopsy during second look surgery at 12-month postoperative.
Change in cartilage thickness from baseline to postoperative 6 months 6-month postoperative Cartilage thickness is assessed by MRI preoperatively and 6-month postoperatively.
Trial Locations
- Locations (1)
Show Chwan Memorial Hospital
🇨🇳Changhua City, Changhua, Taiwan